Surgical outcomes of histopathological stage I pancreatic cancer with special reference to oncological differences between pStage I and ypStage I cases DOI
Naoko Sekiguchi, Hidenori Takahashi, Shogo Kobayashi

и другие.

Surgical Oncology, Год журнала: 2025, Номер 60, С. 102225 - 102225

Опубликована: Апрель 12, 2025

Язык: Английский

Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX DOI
Thomas F. Stoop, Toshitaka Sugawara,

Atsushi Oba

и другие.

JAMA Oncology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 23, 2025

Importance The effect of adjuvant chemotherapy following resection pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) on overall survival (OS) is unclear because current studies do not account for the number cycles regimen. Objective To investigate association with OS, taking into Design, Setting, Participants This retrospective cohort study included patients localized treated 2 to 11 followed by across 48 centers 20 countries from 2010 2018. Patients who died within 3 months surgery were excluded (landmark). Data analyzed February 1 December 31, 2023. Exposures Preoperative eventually chemotherapy. Main Outcomes Measures primary outcome was calculated 3-month landmark. Cox regression analysis, including interaction analyses, performed OS. Results Overall, 767 (median [IQR] age, 62 [55-67] years; 404 [52.7%] male). Adjuvant independently associated prolonged OS (hazard ratio [HR], 0.66; 95% CI, 0.49-0.87), confirmed adjusted curves. analysis assess estimated treatment subgroups statistically significant. forest plot test suggest that lower among receiving 8 more (m)FOLFIRINOX, those had radiological response, ypN0 disease. Compared no chemotherapy, both (HR, 0.57; 0.40-0.80) other multiagent regimens 0.61; 0.41-0.92) whereas single-agent 0.75; 0.55-1.03). Conclusions Relevance In this study, improved not. impact may be such as having ypN0.

Язык: Английский

Процитировано

1

Pancreatic cancer DOI
Thomas F. Stoop, Ammar A. Javed, Atsushi Oba

и другие.

The Lancet, Год журнала: 2025, Номер 405(10485), С. 1182 - 1202

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0

Surgical outcomes of histopathological stage I pancreatic cancer with special reference to oncological differences between pStage I and ypStage I cases DOI
Naoko Sekiguchi, Hidenori Takahashi, Shogo Kobayashi

и другие.

Surgical Oncology, Год журнала: 2025, Номер 60, С. 102225 - 102225

Опубликована: Апрель 12, 2025

Язык: Английский

Процитировано

0